‪Marwa A. sabet‬‏

Dr. ‪Marwa A. sabet‬‏

Sphinx university, Assiut, Egypt
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
OROsamah Al Rugaie
Osamah Al Rugaie
Ahmed A. H. AbdellatifAhmed A. H. Abdellatif
Ahmed A. H. Abdellatif
MEMohamed El-Mokhtar
Mohamed El-Mokhtar
‪S‪Marwa A. sabet‬‏
‪Marwa A. sabet‬‏
AAAhmed Abdelfattah
Ahmed Abdelfattah
HTHesham Tawfeek
Hesham Tawfeek
Urinary catheter infections remain an issue for many patients and can complicate their health status, especially for individuals who require long-term catheterization. Catheters can be colonized by biofilm-forming bacteria resistant to the administered antibiotics. Therefore, this study aimed to investigate the efficacy of silver nanoparticles (AgNPs) stabilized with different polymeric materials generated via a one-step simple coating technique for their ability to inhibit biofilm formation on urinary catheters. AgNPs were prepared and characterized to confirm their formation and determine their size, charge, morphology, and physical stability. Screening of the antimicrobial activity of nanoparticle formulations and determining minimal inhibitory concentration (MIC) and their cytotoxicity against PC3 cells were performed. Moreover, the antibiofilm activity and efficacy of the AgNPs coated on the urinary catheters under static and flowing conditions were examined against a clinical isolate of Escherichia coli. The results showed that the investigated polymers could form physically stable AgNPs, especially those prepared using polyvinyl pyrrolidone (PVP) and ethyl cellulose (EC). Preliminary screening and MIC determinations suggested that the AgNPs-EC and AgNPs-PVP had superior antibacterial effects against E. coli. AgNPs-EC and AgNPs-PVP inhibited biofilm formation to 58.2% and 50.8% compared with AgNPs-PEG, silver nitrate solution and control samples. In addition, coating urinary catheters with AgNPs-EC and AgNPs-PVP at concentrations lower than the determined IC50 values significantly (p < 0.05; t-test) inhibited bacterial biofilm formation compared with noncoated catheters under both static and static and flowing conditions using two different types of commercial Foley urinary catheters. The data obtained in this study provide evidence that AgNP-coated EC and PVP could be useful as potential antibacterial and antibiofilm catheter coating agents to prevent the development of urinary tract infections caused by E. coli.

Verified
Journal Article
Open access
PDF file
Mostafa Farouk Al-HakkaniMostafa Farouk Al-Hakkani
Mostafa Farouk Al-Hakkani
NANourhan Ahmed
Nourhan Ahmed
AAAlaa A. Abbas
Alaa A. Abbas
Mohammad H.A. HassanMohammad H.A. Hassan
Mohammad H.A. Hassan
HAHossameldin Ali Aziz
Hossameldin Ali Aziz
Hamada HashemHamada Hashem
Hamada Hashem
A novel derivative of ciprofloxacin (Cpx) was synthesized and characterized using various analytical techniques, including FT-IR spectroscopy, UV-Vis spectroscopy, TEM and SEM analysis, 1H NMR, 13C NMR, and HPLC analysis. The newly prepared Cpx derivative (Cpx-Drv) exhibited significantly enhanced antibacterial properties compared to Cpx itself. In particular, Cpx-Drv demonstrated a 51% increase in antibacterial activity against S. aureus and a 30% improvement against B. subtilis. It displayed potent inhibitory effects on topoisomerases II (DNA gyrase and topoisomerase IV) as potential molecular targets, with IC50 values of 6.754 and 1.913 µg/mL, respectively, in contrast to Cpx, which had IC50 values of 2.125 and 0.821 µg/mL, respectively. Docking studies further supported these findings, showing that Cpx-Drv exhibited stronger binding interactions with the gyrase enzyme (PDB ID: 2XCT) compared to the parent Cpx, with binding affinities of −10.3349 and −7.7506 kcal/mole, respectively.

Verified
Journal Article
Open access
PDF file
GEGhada M. Ezzat
Ghada M. Ezzat
NANashwa Mostafa A. Azoz
Nashwa Mostafa A. Azoz
RZRanda A. El Zohne
Randa A. El Zohne
HAHebatAllah Abdellatif
HebatAllah Abdellatif
TSTahia H. Saleem
Tahia H. Saleem
MDMarwa A Dahpy
Marwa A Dahpy
Zinc (Zn) and copper (Cu) have been shown to have the potential to improve glucose metabolism through interactions with cytokines and signaling events with multiple genes. miRNA-375 and the Calpin-10 gene are potential genetic biomarkers for the early prediction of diabetic nephropathy (DN). 128 healthy controls and 129 type 2 diabetic (T2DM) participants were matched for age and sex. Three subgroups were identified from the T2DM group: 39 patients had microalbuminuria, 41 had macroalbuminuria, and 49 patients had renal problems. Circulating miR-375 expression levels were measured via qPCR. Calpain-10 SNP 19 (rs3842570) genotyping was assessed with allele-specific PCR in all the included participants. Spectrophotometry was used to measure the concentrations of serum copper, zinc, and magnesium, while ELISA was used to measure the levels of TGF-β and IL-17. There was significant up-regulation in the expression of miR-375 and serum levels of TGF-β, IL-17, Cu, and the Cu/Zn ratio, whereas, in contrast to the control group, the Zn and Mg levels were lower in the T2DM group. The DN groups had significantly lower miR-375, TGF-β, IL-17, Mg, and Zn levels compared with the T2DM without nephropathy group. Furthermore, between TGF-β, IL-17, and miRNA-375, there were notable correlations. Calpain-10 SNP 19 genotype 22 and allele 2 were linked to a higher incidence of T2DM and DN. Significant TGF-β, Cu, Cu/Zn ratio, HbAc1, and creatinine levels, but insignificant miRNA-375 levels, were associated with genotype 22 of Calpain-10 SNP 19. interactions between the Calpain-10 SNP 19 genotype 22 and IL-17, TGF-β, mineral levels, and miRNA-375 might contribute to the aetiology of DN and T2DM and may have clinical implications for diagnosis and management.

13 February 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GEGhadeer Elfaddaly
Ghadeer Elfaddaly
DGDalia M. Ghorab
Dalia M. Ghorab
HSHeba Muneer El sorogy
Heba Muneer El sorogy
SESalwa Sayed Seif Eldin
Salwa Sayed Seif Eldin
‪S‪Marwa A. sabet‬‏
‪Marwa A. sabet‬‏
HThoda El Sayed teba
hoda El Sayed teba
Background/Objectives: Keratitis is an ocular disease caused by microbial infection or by non-infectious damage due to UV light exposure, chemical exposure, or eye injuries. Methods: Moxifloxacin-loaded ufasomes (MOX-UFAs) were optimized using a full factorial design (12.23) after being prepared by the vortex mixing method. The study evaluated the effects of the oleic acid amount, surface active agent (SAA) amount, and SAA type as independent factors on the entrapment efficiency percent (EE%), particle size (PS), polydispersity index (PDI), zeta potential (ZP), and the amount released after 6 h (Q6h%). Results: The optimized ufasomes (UFAs) formulation was spherical, with an EE% of 78.37 ± 3.91%, PS of 203.13 ± 20.31 nm, PDI of 0.334 ± 0.016, and ZP of −25.42 ± 1.27 mV. The in vitro release of moxifloxacin (MOX) from the UFAs was maintained for more than 6 h in the range of 40.0–75.0%. The optimum MOX-UFAs formulation was incorporated into an in situ gel (Pluronic F-127/HPMC K4M). The ex vivo studies (corneal permeation and confocal laser scanning microscopy) proved the successful retention of the MOX-UFAs-laden in situ gel. Furthermore, the in vitro and in vivo antimicrobial studies revealed their significant antimicrobial effect against Pseudomonas aeruginosa. In addition, the Draize test proved the tolerability of MOX-UFAs-laden in situ gel in animals. Conclusions: The incorporation of MOX-UFAs into Pluronic F-127/HPMC K4M in situ gel could successfully provide sustained ocular delivery and improve the bioavailability of MOX for the management of keratitis.

9 May 2020 in Bulletin of Pharmaceutical Sciences. Assiut
Verified
Journal Article
Closed access
‪S‪Marwa A. sabet‬‏
‪Marwa A. sabet‬‏
EDEnas Deaf
Enas Deaf
DGDoaa Ghaith
Doaa Ghaith
MAMichael Agban
Michael Agban
SESherine Abd Elrahman
Sherine Abd Elrahman
The quinolone antibiotics arose in the early 1960s, with the first example having a narrow spectrum of activity with unfavourable pharmacokinetics. Over time, the development of new quinolone antibiotics has led to improved equivalents with an expanded spectrum and high efficacy. Nowadays, quinolones are broad-spectrum antibiotics that are active against both Gram-positive and Gram-negative bacteria, as well as mycobacteria, and anaerobes. They exert their actions by inhibiting bacterial nucleic acid synthesis through disrupting the enzymes topoisomerase IV and DNA gyrase, and by causing damage of bacterial chromosomes. Acquired bacterial resistance to quinolones rises due to the abuse of these drugs. Mechanisms contributing to quinolone resistance are mediated by chromosomal mutations and/or plasmid gene uptake that modify topoisomerase targets, modify the quinolone, and/or reduce drug accumulation by either decreased uptake or increased efflux. This review describes the history of development of this class of antibiotics, different generations, mechanism of action, along with the resistance mechanisms which reduce the quinolones' activities against different microorganisms.